Background The study was conducted to assess differences in overall survival (OS) in
patients with non‐small cell lung cancer (NSCLC) receiving different treatment modalities of …

For patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the
relationship between the dose or duration of treatment with tyrosine kinase inhibitor (TKI) …

Direct comparisons between the use of first-and second-line EGFR tyrosine kinase inhibitor
(TKI) in patients with sensitive EGFR mutations are limited. A total of 264 advanced non …

BACKGROUND: There is no published overview of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …

Background/Aim: Epidermal growth factor receptor (EGFR) mutation testing is standard-of-
care for advanced non-small cell lung cancer (NSCLC). Outcomes of second-/third-line …

Background Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has
a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to …

Background Nowadays, patients with EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitive
advanced non-small cell lung cancer (NSCLC) receive EGFR-TKIs as first-line treatment. We …

Results In total, 521 patients were administered EGFR-TKI. Of these, 298 patients received
EGFR-TKI with progression-free survival less than 6 months (group A), and the other 223 …

Background In the first line treatment of non-small cell lung cancer (NSCLC), several clinical
trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase …

Purpose: To compare survivals between unresectable stage III and stage IV EGFR-mutated
non-small cell lung cancer (NSCLC) patients receiving first-line EGFR-TKI. Materials and …